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Abstract
Noroviruses (NV) are +ssRNA viruses responsible for severe gastroenteritis; no effective vaccines/antivirals are currently
available. We previously identified Suramin (9) as a potent inhibitor of NV-RNA dependent RNA polymerase (NV-RdRp).
Despite significant in vitro activities versus several pharmacological targets, Suramin clinical use is hampered by
pharmacokinetics/toxicity problems. To improve Suramin access to NV-RdRp in vivo, a Suramin-derivative, 8, devoid of two
sulphonate groups, was synthesized, achieving significant anti-human-NV-RdRp activity (IC50 = 28 nM); the compound
inhibits also murine NV (mNV) RdRp. The synthesis process led to the isolation/characterization of lower molecular weight
intermediates (3–7) hosting only one sulphonate head. The crystal structures of both hNV/mNV-RdRps in complex with 6,
were analyzed, providing new knowledge on the interactions that a small fragment can establish with NV-RdRps, and
establishing a platform for structure-guided optimization of potency, selectivity and drugability.
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Introduction
Norovirus (formerly Norwalk-like virus, NV) is a genus of the
Caliciviridae family that is a major causative agent of non-bacterial
acute gastroenteritis in humans. Outbreaks commonly occur in
settings such as hospitals, nursing homes, cruise ships, university
dormitories, and military barracks. It is estimated that NV
infection may account for up to 200,000 deaths per year in
infants and young children of the developing countries [1], [2].
Currently, no vaccines [3], [4] or specific antiviral agents are
available to combat NV; thus, there is an urgent and still unmet
need for discovery and development of broad spectrum small-
molecule therapeutics against this severe pathogen. Human NVs
are fairly species-specific and do not appear to infect small
animals, even if animal models are under development [5], [6],
[7]. A widely used model system shedding light on NV
pathogenesis and replication strategies is the murine model of
NV infection, obtained by infecting mice with murine NVs
(mNVs) [8]. The calicivirus genomes consist of a single stranded,
positive-sense poly-adenylated RNA molecule that averages 7500
nucleotides in length. It is organized in either two or three open
reading frames (ORF-1 to ORF-3), depending on the particular
genus. ORF-1 is predicted to encode a single polyprotein that,
after co-translational processing by the viral protease, results in the
nonstructural proteins required for replication of the viral genome
[9], [10] and their precursors [11]. Among these, nonstructural
protein 7 [RNA-dependent RNA polymerase (RdRp) domain]
plays a key role in genome replication, as well as in the synthesis
and amplification of additional subgenomic RNA [12]. Notably,
since RdRp is not present in mammalian cells, it appears as a
suitable target for inhibition in the context of antiviral prophylaxis.
Suramin (9, Fig. 1) is a polysulphonated naphthylurea, which has
been used as the drug of choice for treatment of African
trypanosomiasis and onchocerciasis since 1924 [13]. Different
Suramin applications have been reported, including inhibition of
reverse transcriptase [14], P2X and P2Y nucleotide receptor
family antagonism [15], [16], and blocking actions on various
growth factors [17]. Also, since Suramin hinders cell proliferation
and migration, as well as the formation of new blood vessels, it has
been tested for potential use as an anticancer agent [18];
moreover, Suramin was noted to induce hyperglycaemia [19],
[20]. Several clinical trials based on Suramin and Suramin-like
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compounds have nevertheless proven unsatisfactory, as in vitro
results did not translate into the desired clinical response in vivo.
Except for trypanosomiasis, in fact, all other trials did not reach
the clinical level due to challenges related to Suramin pharma-
cokinetics and toxicity [20], [21], [22]. We previously identified
Suramin as a potent inhibitor of hNV and mNV-RdRps, and
solved the crystal structures of mNV RdRp in the absence/
presence of Suramin, highlighting an inhibitor binding site located
between the RdRp fingers and thumb domains. In particular, the
cleft occupied by the inhibitor is lined with conserved amino acids,
likely building the access route for the incoming NTP that will be
linked to the nascent RNA chain. [23]. Due to the high potency of
Suramin in enzymatic assays, its optimization into a more drug-
like compound would not require enhancing its interaction with
the therapeutic target (e.g. hNV-RdRp), rather it should improve
the ability of Suramin to reach the therapeutic target in vivo.
Suramin is a polar compound, with log P value lower than 0; thus,
it is likely to traverse the epithelium slowly via paracellular
channels. In addition, it should be recalled that Suramin’s high
molecular weight (1429 Da) might promote biliary excretion,
reducing its overall systemic bioavailability [24], [25].
The crystal structure of mNV-RdRp in complex with Suramin
showed that only two of the three sulphonate groups on the
Suramin naphthalene rings establish ionic interactions with basic
residues of the enzyme [23]. On the basis of such structural
information we undertook the chemical synthesis and biochemical
characterization of carbamide 8 (see Fig. 1), a Suramin derivative
bearing only two sulphonate groups on each naphthalene ring, as
a first optimization step. We then characterized 8, together with
lower molecular weight synthetic reaction intermediates, in
enzymatic inhibition assays versus hNV and mNV RdRps. To
further address the inhibitory mechanistic issues, and to gather
new information for rational drug design, we then analyzed the
crystal structures of both hNV and mNV-RdRps in their
complexes with diamide 6, one of the reaction intermediates
hosting only one sulphonate head, showing a favorable log P value
relative to Suramin.
Aiming to further develop anti-norovirus compounds, we report
here the details of the synthetic steps to produce five inhibitors, the
analysis of their hNV and mNV-RdRp inhibitory activities,
together with the crystal structure analysis of hNV and mNV-
RdRps in their complexes with 6, a low molecular weight
representative compound in this class.
Results
Syntheses and Spectral Characteristics of Carbamide 8
For examination of the effects resulting from the sulphonate
group (in position 3) of compounds in the family of Suramin (9), a
total synthesis of carbamide 8 was performed as shown in Fig. 1.
The condensation of commercially available nitrobenzoyl chloride
1 with sodium naphthalene disulphonate 2 in water at pH 4.0
yielded nitroamide 3 in 81% yield. Reduction of the nitro group in
compound 3 with hydrogen gas in the presence of Pd catalyst led
to the corresponding aniline 4 in excellent yield; meanwhile, the
two aryl groups remained intact. A repeat of the same type of
condensation reaction by use of aniline 4 and benzoyl chloride 5
afforded the desired diamide 6, which was further hydrogenated to
give stable sodium salt of aniline 7. Solubility of this compound
was found very poor in most of organic solvents, including THF
and DMSO. The carbonylation of aniline 7 with 1, 19-
carbonyldiimidazole (CDI) [26] in a mixture of water and toluene
in different ratios at room temperature or under reflux conditions
did not lead to the desired carbamide 8. Instead, the starting
materials remained intact. This problem was circumvented by use
of triphosgene in a slight excess to react with aniline 7 at pH 3.0 in
an aqueous Na2CO3 solution containing toluene. Accordingly, 8
was generated as a white powder in 83% yield.
The structures of sulphonates 3–8 were confirmed by their
spectroscopic characteristics. For instance, the exact mass of
carbamide 8 (C51H36N6Na4O17S4+2 Na)2+ was measured by the
electrospray ionization (ESI) method as 635.0116, which is very
close to its theoretical value of 635.0197. Its 13C NMR spectrum
displayed 26 peaks as expected; among which the peak with
d= 153.53 was attributed to the carbamido carbon (i.e. NCON).
Two peaks at d= 165.81 and 165.06 in the downfield region
belonged to the two different amide carbons. Its 1H NMR
spectrum showed nine sets of peaks, which resonated between
9.09–7.37 ppm with singlet, doublet, and triplet. They were
associated with the aromatic protons with the expected splitting
pattern for carbamide 8. Its IR spectrum exhibited strong
absorptions at 1652 and 1634 cm21, which were attributed to
the stretching vibration of an amido carbonyl group.
Physical and Biological Properties of Sodium
Organosulfonates 3–8 and Suramin (9)
Bookser’s method [27] was applied to obtain the water solubility
of sodium organosulphonates 3–8 and Suramin (9) by use of
HPLC with a UV detector (see Table 1). Furthermore, the
‘‘shake–flask method’’ [28] was applied to obtain their hydropho-
bicity by use of n-octanol and water. The apparent partition
coefficient (P) shown in Table 1 is the ratio of the concentration in
n-octanol to the total concentration (i.e., ionized plus non-ionized)
of the species in the aqueous phase, [29].
Enzymatic assays
hNV and mNV-RdRp inhibition assays were performed
monitoring the impairment of RNA synthesis as a function of
inhibitor concentration, as previously described [23]. Briefly,
RdRp activity was assessed in vitro (measuring PicoGreen
fluorescence) following the synthesis of double-stranded RNA
from a single-stranded RNA poly(C) template annealed with a G12
primer. The assay can easily be adapted for any viral RNA
polymerase [30]. Under our experimental conditions, 8 inhibited
hNV-RdRp with the same IC50 value of Suramin (,30 nM),
whereas 6 and other synthetic intermediates proved to be ,30–
35-fold less potent (Table 2). All the low molecular weight
compounds (3–7) are generally more potent inhibitors of mNV
rather than of hNV-RdRp (Table 2).
Thermofluorimetric assays
In order to exclude that 8 and 6 inhibition might be linked to
some form of RdRp destabilization/aggregation/denaturation, a
process generally reflected by a variation of the protein melting
temperature (Tm), we performed thermofluorimetric assays on free
and inhibited NV-RdRps. All the acquired data showed that NV-
RdRps displays similar melting temperatures in the absence
(hNV/mNV-RdRp Tm = 41.5/39.6 60.2 uC), or in the presence
of 6 (hNV/mNV-RdRp Tm = 41.260.2/39.460.3 uC), or of 8
(hNV/mNV-RdRp Tm = 41.4/39.8 60.2 uC), thus proving that
enzyme inhibition is not caused by denaturation of the protein.
Crystal structures of NV-RdRps bound to 6
To shed light on the mechanisms of RdRp inhibition exerted by
the organic sulphonate compounds described above, we undertook
crystallographic analyses of both enzymes in their complexes with
6. To address the crystal structures of the 6 adduct, hNV-RdRp
Suramin-Related Compounds Inhibit Norovirus RdRp
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Figure 1. Suramin derivative 8 synthesis. Total synthesis of Suramin derivative 8 from commercially available starting materials. The Suramin
molecule (9) is also shown for comparison.
doi:10.1371/journal.pone.0091765.g001
Table 1. Water solubility and hydrophobicity of organic
sulphonates 3–8 and Suramin.
Compound water solubilitya (mg/ml) hydrophobicityb log P
3 260 22.19
4 339 22.33
6 179 21.64
7 249 22.11
8 114 21.61
Suramin (9) 138 23.42
aThe Bookser’s method was applied.
bThe shake–flask method was applied.
doi:10.1371/journal.pone.0091765.t001
Table 2. IC50 values of Suramin derivatives and Suramin (9)
against mNV and hNV-RdRps.
IC50 (nM)
Compound mNVRdRp hNVRdRp
3 200610 1280670
4 16067 11006200
6 115615 1000690
7 16066 1100650
8 6064 2864
Suramin (9) 7063 2763
doi:10.1371/journal.pone.0091765.t002
Suramin-Related Compounds Inhibit Norovirus RdRp
PLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e91765
Figure 2. Superposition of hNV and mNV-RdRp/6 complex structures. Superposition of the crystal structures of hNV-RdRp in cartoon
(magenta) bound to 6 (yellow carbon atoms) in sticks, onto mNV-RdRp in cartoon (blue), bound to 6 (carbon atoms in green) in sticks. The suramin
position (in sticks orange carbons) is obtained from superposition of pdb-id 3UR0 (Mastrangelo et al., 2012) (Figures created using PyMol (http://
www.pymol.org)).
doi:10.1371/journal.pone.0091765.g002
Table 3. X-ray data-collection and refinement statistics for the hNV-RdRP/6 complex.
Protein crystals hNV-RdRp/6 mNV-RdRp/6
6 concentration (mM) 10 20
Resolution (A˚) 71.80–2.02 64.96–2.30
Space group I222 P21
Unit-cell parameters (A˚, u) a = 89.2; b = 112.0; c = 121.1 a = 109.2; b = 162.4; c = 123.0 b= 97.0u
Molecules in a.u. 1 6
Mosaicity (u) 0.2 0.3
Unique reflections 39,356 (5,729)* 188,102 (27,425)*
Completeness (%) 98.8 (99.1) 99.9 (99.8)
Redundancy 3.1 (3.2) 3.2 (3.2)
Rmerge{ (%) 8.4 (30.5) 9.8 (72.0)
Average I/s (I) 8.4 (3.4) 7.7 (1.6)
R factor`/Rfree1 (%) 16.4/20.9 19.1/25.4
r.m.s.d. bonds (A˚) 0.011 0.010
r.m.s.d. angles (u) 1.48 1.33
Average protein B factors (A˚2) 28.2 A = 38.4, B = 39.9, C = 42.0, D = 42.9, E = 49.5, F = 58.4
Average ligand B factors (A˚2) 55.6 A = 78.2, B = 58.9, C = 70.2, D = 67.3, E = 85.5, F = 87.7
Residues in most favored regions (%) 95.0 92.9
Residues in additionally allowed regions (%) 5.0 7.1
PDB 4NRT 4NRU
*Values in parentheses are for the highest resolution shell: (2.13–2.02 A˚ for hNV RdRp/6, 2.42–2.30 A˚ for mNV RdRp/6).
{Rmerge =S |I2(I)|/S I x 100, where I is intensity of a reflection and (I) is its average intensity.
`R factor =S |Fo2Fc|/S |Fo| x 100.
1Rfree is calculated on 5% randomly selected reflections, for cross-validation.
doi:10.1371/journal.pone.0091765.t003
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and mNV-RdRp crystals were soaked in stabilizing solutions of 6
at concentration of 10 or 20 mM (see Materials and Methods for
details).
hNV-RdRp/6 diffraction data were collected at 100 K at the
ESRF beam line ID29 (Grenoble, France); the crystal structure
was solved by molecular replacement (MR) and refined to final
crystallographic R-factor/R-free values of 16.4/20.9%, at 2.02 A˚
resolution (Table 3). After the first refinement cycles residual
electron density was visible in a positively charged cleft within the
polymerase thumb domain, in a location different from the
Suramin binding site [23] (Fig. 2). The naphthalene sulphonate
head of 6, the linked amido group and the phenyl methyl group
were accordingly modeled in the new site formed by the a13-b-
loop-a14 secondary structure elements (Fig. 2). However, density
for the remaining part of the compound was not visible, as
confirmed by an independent dataset collected after soaking hNV-
RdRp crystals at 20 mM concentration of 6. The naphthalene
ring of 6 is sandwiched between the amido groups of Gln414/
Gln439 on one side, and Phe28/Arg419, on the other. The
negative charges of the two sulphonates are balanced by residues
Arg419, Arg436, and likely (considering that the soaking took
place at pH 6) by His433. In particular the sulphonate in position
1 is highly stabilized by an electrostatic interaction network
involving the side chains of Thr418, His433, Arg436, and the
main chain nitrogen of Arg419 (Fig. 3A). The unmodeled tail of 6
would be hosted in the polar central region of the enzyme which
accommodates dsRNA during elongation, wide enough to allow
conformational flexibility of the second half of the inhibitor, in
keeping with the lack of an interpretable electron density signal.
mNV-RdRp/6 diffraction data were collected at 100 K at the
ESRF beam line ID29 (Grenoble, France); the crystal structure
was solved by MR (2.3 A˚ resolution) and refined to final
crystallographic R-factor/R-free values of 18.5/24.8% (see
Materials and Methods and Table 3). Six mNV-RdRp molecules
are hosted in the crystal asymmetric unit. Inspection of the refined
model shows that the naphthalene disulphonate head of the
inhibitor binds to the same RdRp location identified for hNV-
RdRp (Fig. 2). In the murine protein compound 6 could be fully
modeled in all the subunits of the crystal asymmetric unit (Fig. 3B).
Relative to the hNV/6 binding mode described above, in mNV
RdRp the naphthalene ring of the molecule is found slightly
repositioned, showing a rotation of the naphthalene plane of about
20u toward the palm domain, and a translation away from the a14
helix (by 1.3 A˚, Fig. 3C). The observed roto-translation of the
ligand is related to the loss of the interaction with Gln439 and with
His433, both pointing toward the solvent in mNV RdRp (Fig. 3C).
Such shift of the ligand molecule promotes the stacking interaction
of the toluene group of 6 with Arg392 guanidine moiety (H-
Figure 3. Interaction network of hNV and mNV-RdRp/6 complex. A) Fragment of 6 (carbon atoms in yellow) bound to hNV-RdRp in cartoon
(magenta). All the amino acids involved in interaction with the inhibitor molecule are shown in sticks (carbon atoms in magenta). B) 6 (carbon atoms
in green) bound to mNV-RdRp in cartoon (blue). All the amino acids (carbon atoms in blue) involved in interaction with the molecule are shown in
sticks. 2Fo-Fc electron density contoured at 1 sigma in blue grid. C) Superposition of hNV-RdRp and mNV-RdRp, showing the structures of 6 (carbon
atoms in yellow/green, respectively) bound to hNV-RdRp and to mNV-RdRp (cartoon in magenta/blue, respectively). The interacting amino acids are
shown in sticks (magenta/blue carbon atoms, respectively).
doi:10.1371/journal.pone.0091765.g003
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bonded to 6 carbonyl, and in electrostatic interaction with 2
sulphonates), which allows the stabilization of the entire inhibitor
(Fig. 3B, C).
Discussion
For the successful synthesis of sodium sulfates 3, 6 and 8, it was
crucial to maintain the pH values of the media throughout the
entire processes at 4.0 for conversion of 2R3, and at 3.0 for the
4R6 and 7R8 conversions. An aqueous Na2CO3 solution (2.0 M)
was frequently added to the reaction mixtures; otherwise, the pH
values would be reduced to ,1 during the course of the reactions.
High care was taken during the coupling of aniline 7 with
triphosgene, which may decompose to an insidious poison
phosgene gas during the carbonylation reaction. Accordingly,
control of its pH value and addition of a Na2CO3 solution were
performed in a closed system by a syringe. Although phosgene can
be used in the synthesis of urea by reacting with amines [24], two
advantages are associated with triphosgene: i) being a solid,
triphosgene is safer to handle than phosgene, which is a gas or a
toluene solution; ii) a stoichiometric amount of triphosgene suffices
for urea formation, which proceeded in a good yield. Solubility of
chemical entities in water plays an important role in their
development as a lead for new drugs [24] and is related to the
structure–activity relationship. Poor water solubility of a com-
pound may result in decreased oral absorption regardless of its
good permeation rate across the intestinal mucosa into the
circulation. The apparent partition coefficient (P), which is a useful
parameter for understanding the behavior of drug molecules, was
measured. Often it is used to predict the distribution of a drug
compound in a biological system, the log P value being related to
absorption, excretion, and penetration [31]. The measurement of
the apparent partition coefficient provides a simple ‘‘in vitro’’
method to predict the behavior of a compound in the body and to
select the most promising drug candidates from a large pool of
ionizable compounds. Thus the log P of thousands of drugs and
potential drugs has been measured over the years. Our results
presented in Table 1 indicate that the water solubility fell into the
range of 114–339 mg/ml for compounds 3–8. Carbamide 8
containing four hydrophilic sulphonate groups was less water
soluble than Suramin (114 versus 138 mg/ml), which contained
six sulphonate groups. The new 8 also showed a better
hydrophobicity than Suramin (log P –1.61 versus –3.42).
It is important to notice that in the DrugBank database (www.
http://www.drugbank.ca/), containing 1442 drugs with measured
log P between -9 and +10 (average value 2.0, standard deviation
2.2), only 2.1% of the molecules have log P values comprised
between 24 and 23, while for 5.6% of the database this value
ranges between 21 and 22.
Enzymatic inhibition assays performed on hNV and mNV-
RdRps showed that 8 retains potent inhibition activity with IC50
values (ca. 30 nM for hNV-RdRp and ca. 60 nM for mNV) that
are fully comparable with those of Suramin reported earlier [23].
Notably, the Suramin IC50 values previously reported were
crosschecked in the present study, under the experimental
conditions here reported, employing the same enzyme preparation
used for assaying 6 and 8 inhibitions. The low nanomolar IC50
displayed by 8 is in keeping with its close structural relationship
with Suramin. Moreover, the observation that 8 inhibitory
potency vs. NV-RdRps was conserved (relative to Suramin)
supports our structure-based hypothesis that the sulphonate group
at position 3 of the naphthalene head (removed in 8) is not
involved in the RdRp recognition mechanism. Smaller Suramin-
related compounds, isolated during the synthetic steps leading to
8, were found to be less potent inhibitors, relative to Suramin (9)
and 8 (Table 2). Nevertheless, the effects exerted to the targeted
enzymes were sufficient to drive structural experiments. Since
Suramin and 8 showed an almost identical IC50 value and close
structural formulas, we focused on 6 whose smaller size may allow
mapping new regions in the enzyme active site. In particular, 6 is a
non-symmetric fragment of 8 hosting only one naphthalene
disulphonate head. From a structural viewpoint, 6 can be seen as
composed of two distinct parts: the naphthalene disulphonate acid
head, which is involved in main interactions with the enzyme at
the newly mapped binding site, and the tail region (composed of a
toluene and a nitrobenzene ring linked by an amide group), which
may provide additional interactions outside the main contact
region. Inspection of the crystal structures showed that 6 binds to a
site located in the polymerase thumb domain, more specifically in
a cleft along the exit path for the newly synthesized RNA. This site
doesn’t match the previously identified Suramin binding site, but
corresponds to the Pyridoxal-59-phosphate-6-(29-naphthylazo-69-
nitro-49,89-disulphonate; PPNDS) [32], [33] binding site [34](Tar-
antino et al. in press). Notably, PPNDS is also a molecule
composed of two parts: the naphthalene disulphonate head and
the pyridoxal phosphate group, linked by an azo bridge.
Our analysis on the NV-RdRp/6 complex crystal structure
shows that the sulphonate groups on the naphthalene sulphonic
head interact with the RNA binding loop (residues 433–440). The
crystal structures of hNV-RdRp/RNA complexes (3BSO and
3H5X) [35], [36] revealed significantly different locations in the
RNA-binding loop relative to the free RdRp, showing specific
RNA-induced conformational changes of this loop [37]. Binding
of compound 6 might freeze the loop in hNV RdRp in the
conformation found in the free enzyme hindering efficient RNA
binding.
In the hNV-RdRp/6 complex, the inhibitor electron density
fades rapidly after the amido group linked to the naphthalene
disulphonate moiety. The latter, in fact, is shifted toward His433
and tilted by steric hindrance with the Gln439/Gln414 ‘‘floor’’
(Fig. 3A,C), thus leaving the unmodeled part of 6 in an open
enzyme region that fails to stabilize the ligand in one conforma-
tion. Thus, the lower inhibitory potency of 6 vs. hNV-RdRp may
be linked to failure of establishing enzyme/inhibitor stabilizing
interactions along the whole inhibitory molecule, which appears to
remain mobile for about 50% of its scaffold.
On the contrary in the mNV-RdRp/6 structure, the inhibitor
could be completely modeled thanks to the different disposition of
the naphthalene head due to the loss of the interaction with
His433. The new interactions of 6 with Arg392 and Arg393 are in
agreement with the higher potency of 6 vs. mNV-RdRp relative to
hNV-RdRp. In contrast, 8 shows a slightly lower inhibitory effect
on mNV relative to hNV-RdRp as observed for Suramin,
probably because it binds to the same binding site of the latter
inhibitor, achieving a different interaction network with the
protein. The current crystal structure data, available only for the
mNV-RdRp/Suramin complex (Mastrangelo et al.,2012) do not
allow further comparisons.
The newly discovered NV-RdRP inhibitor binding site, mapped
by 6 and by PPNDS, together with the different conformational
behaviors displayed by 6 bound to hNV and mNV-RdRps, appear
as two novel structural grounds to be exploited for the design and
development of more potent/selective hNV-RdRp inhibitors.
Conclusions
This study presented the design and synthesis of a modified
Suramin molecule (8), the crystal structure analyses of NV-RdRps
Suramin-Related Compounds Inhibit Norovirus RdRp
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in complexes with a Suramin fragment (6), and the evaluation of
inhibitory parameters for five related compounds targeting mNV
and hNV-RdRps. A total synthesis of 8 from commercially
available reagents was accomplished, which involved five steps
with a 45% overall yield. In comparison with Suramin (9) bearing
six hydrophilic sulphonate groups, the new and symmetric 8
contains four sulphonate groups, and exhibits the same potency as
Suramin against NV-RdRps. However, its water solubility and log
P value are more favorable compared to Suramin. In contrast, the
tested reaction intermediates proved less effective in inhibiting NV
polymerases.
Analysis of the crystal structures of hNV-RdRp/6 complexes
provided a mechanistic explanation of the decreased potency
displayed by this compound. In fact, although the inhibitor
naphthalene disulphonate ‘head’ is strongly bound to a specific
pocket in the hNV-RdRp thumb domain, the rest of the molecule
is hardly involved in enzyme/inhibitor interactions, negatively
affecting 6 affinity for the polymerase active region. On the
contrary, the higher inhibitory potency of 6 against mNV-RdRp
correlates with a fully defined binding mode and interactions of
the inhibitor to the RdRp active site. It may be noted that the
related PPNDS NV-RdRp inhibitor, which displays a lower
molecular weight and an overall more rigid structure, while
adopting the same binding mode for the naphthalene disulphonate
moiety, is involved in strong interactions with the enzyme in the
naphthalene disulphonate substituent region, and displays low nM
inhibitory potency [34] (Tarantino et al., in press). The basic
structural and functional knowledge here reported for Suramin
fragments, and particularly for 6, will guide further Suramin
chemical modifications aimed at the identification of hNV-RdRp
inhibitors potentially able to be developed as anti-Norovirus
agents.
Materials and Methods
General Procedure
All reactions were carried out in oven-dried glassware (120 uC)
under an atmosphere of nitrogen unless otherwise indicated.
Acetone, diethylether, toluene, acetic acid, and methanol were
purchased from Mallinckrodt Chemical Co. 4-Amino-1,5-
naphthalenesulphonate acid monosodium salt and triphosgene
were purchased from TCI Chemical Co. 4-Methyl-3-nitrobenzoyl
chloride was purchased from Sigma–Aldrich Chemical Co. Pd/C
(10%) was purchased from Alfa Aesar Chemical Co. 3-Nitroben-
zoyl chloride was purchased from Across Organics Chemical Co.
Analytical thin layer chromatography (TLC) was performed on
precoated plates (silica gel 60 F–254), purchased from Merck Inc.
High performance liquid chromatography (HPLC) was performed
on two Waters 515 HPLC Pumps equipped with a Waters
2489 UV/Visible Detector and a Thermo 5 mm Hypersil ODS
(25064.6 mm D.I.). Purity of products 3, 4, 6, 7, and 8 was
.98.0%, as checked by HPLC. Infrared (IR) spectra were
measured on a Perkin–Elmer model spectrum one B spectropho-
tometer and Perkin–Elmer Spectrum 100 FT-IR Spectrometer.
Absorption intensities are recorded by the following abbreviations:
s, strong; m, medium; w, weak. Proton NMR spectra were
obtained on a Varian Mercury-400 (400 MHz) spectrometer or a
Bruker AV-400 (400 MHz) by use of DMSO-d6 as solvent. Proton
NMR chemical shifts are referenced to the DMSO-d6 quintet (d
2.49 ppm). Carbon-13 NMR spectra were obtained on a Varian
Mercury-400 (100 MHz) spectrometer or a Bruker AV-400
(100 MHz) by use of DMSO-d6 as solvent. Carbon-13 chemical
shifts are referenced to the center of the DMSO-d6 septet (d
39.5 ppm). Multiplicities are recorded by the following abbrevi-
ations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; J,
coupling constant (hertz). High-resolution mass spectra were
obtained by means of a VARIAN-901 mass spectrometer.
4-(4-Methyl-3-nitrobenzamido)naphthalene-1,5-
disulphonate Acid Disodium Salt (3)
4-Amino-1,5-naphthalenedisulphonate acid monosodium salt
(2, 0.998 g, 3.07 mmol, 1.0 equiv) was dissolved in water (12 ml)
and the pH was adjusted to 4.0 by addition of aqueous Na2CO3
solution (2.0 M). To this solution 4-methyl-3-nitrobenzoyl chloride
(1, 0.863 g, 4.33 mmol, 1.4 equiv) in toluene (2.7 ml) was slowly
added. Its pH value was maintained continuously at 4.0 by
addition of aqueous Na2CO3 solution (2.0 M). After the reaction
mixture was stirred at room temperature for 12 hours, the toluene
layer was separated out and the pH value of the aqueous layer was
adjusted to 2.0. The aqueous layer was washed with diethyl ether
(4610 ml) and then pH was adjusted to 7.0 by addition of aqueous
Na2CO3 solution (2.0 M). The water was removed under vacuum
at 45 uC to give a crude solid, which was then dissolved in boiling
methanol followed by hot filtration. The residue was dried over
P2O5 under vacuum to give 3 (1.27 g, 2.49 mmol) in 81% yield, as
a pale yellow powder: 1H NMR (DMSO-d6, 400 MHz) d 12.81 (s,
1 H, NH), 9.10 (d, J = 8.8 Hz, 1 H, ArH), 8.66 (s, 1 H, ArH), 8.38
(d, J= 8.0 Hz, 1 H, ArH), 8.29 (d, J= 8.0 Hz, 1 H, ArH), 8.03-
8.02 (m, 2 H, ArH), 7.66 (d, J = 8.0 Hz, 1 H, ArH), 7.47 (t,
J = 8.0 Hz, 1 H, ArH), 2.60 (s, 3 H, CH3);
13C NMR (DMSO-d6,
100 MHz) d 163.32 (C = O), 148.71, 141.65, 141.56, 135.61,
134.72, 133.70, 132.76, 132.32, 131.56, 130.83, 127.20, 124.46,
123.99, 123.54, 123.44, 122.51, 19.52; IR (KBr) 3359 (br, NH),
2918 (s), 1647 (m, C = O), 1547 (m), 1522 (m), 1346 (m), 1195 (s),
1044 (m) cm21; MS (ESI) m/z (M+Na)+ 533, (M+H)+ 511; HRMS
(ESI) calc. for (C18H12N2Na2O9S2+H)+: 510.9858, found
510.9845.
4-(3-Amino-4-methylbenzamido)naphthalene-1,5-
disulphonate Acid Disodium Salt (4)
Nitro compound 3 (0.404 g, 0.792 mmol, 1.0 equiv) was
dissolved in water (5.0 ml), to which 10% Pd/C (20.0 mg, 5.0%
weight of 3) was added. After the reaction mixture was stirred at
room temperature for 12 hours under H2 atmosphere (4.0 bar),
the Pd/C was filtered off by use of celite pad. Water was removed
under vacuum at 45 uC to give a crude solid, which was then
dissolved in boiling methanol followed by hot filtration. The
residue was dried over P2O5 under vacuum to give 4 (0.347 g,
0.722 mmol) in 91% yield, as a brown powder: 1H NMR (DMSO-
d6, 400 MHz) d 12.37 (s, 1 H, NH), 9.08 (d, J = 8.4 Hz, 1 H,
ArH), 8.29 (d, J= 7.2 Hz, 1 H, ArH), 8.03 (d, J= 8.4 Hz, 1 H,
ArH), 7.97 (d, J= 8.4 Hz, 1 H, ArH), 7.46 (t, J= 8.4 Hz, 1 H,
ArH), 7.31–7.28 (m, 2 H, ArH), 7.01 (d, J= 7.6 Hz, 1 H, ArH),
5.06 (br, 2 H, NH2), 2.12 (s, 3 H, CH3);
13C NMR (DMSO-d6,
100 MHz) d 166.25 (C = O), 146.14, 141.89, 140.74, 134.85,
134.14, 131.56, 130.61, 129.32, 126.85, 124.48, 124.33, 123.42,
123.31, 122.10, 115.94, 113.93, 17.44; IR (KBr) 3445 (br, NH),
2918 (w), 1652 (m, C = O), 1575 (s), 1546 (s), 1525 (s), 1414 (m),
1344 (m), 1193 (s), 1073 (w), 1044 (s), 847 (w) cm21; MS (ESI) m/z
(M+Na)+ 503, (M+H)+ 481; HRMS (ESI) calcd for
(C18H14N2Na2O7S2+H)+: 481.0116, found 481.0115.
4-[4-Methyl-3-(3-
nitrobenzamido)benzamido]naphthalene-1,5-
disulsulphonate Acid Disodium Salt (6)
Aniline derivative 4 (0.197 g, 0.410 mmol, 1.0 equiv) was
dissolved in water (3.0 ml) and the pH was adjusted to 3.0 by
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addition of aqueous CH3CO2H solution. To this solution m-
nitrobenzoyl chloride (5, 0.110 g, 0.593 mmol, 1.43 equiv) in
toluene (0.60 ml) was slowly added. Its pH value was maintained
again at 3.0 by addition of aqueous Na2CO3 solution (2.0 M).
After the reaction mixture was stirred at room temperature for
12 hours, the toluene layer was separated out and the pH value of
the aqueous layer was adjusted to 2.0. The aqueous layer was
washed with diethyl ether (465 ml) and then pH was adjusted to
7.0 by addition of aqueous Na2CO3 solution (2.0 M). Water was
removed under vacuum at 45 uC to give a crude solid, which was
then dissolved in boiling methanol followed by hot filtration. The
residue was dried over P2O5 under vacuum to give 6 (0.212 g,
0.337 mmol) in 82% yield as a yellow powder: 1H NMR (DMSO-
d6, 400 MHz) d 12.62 (s, 1 H, NH), 10.59 (s, 1 H, NH), 9.09 (d,
J = 8.4 Hz, 1 H, ArH), 8.85 (s, 1 H, ArH), 8.50 (d, J = 8.0 Hz, 1
H, ArH), 8.45 (d, J = 8.4 Hz, 1 H, ArH), 8.29 (d, J= 7.2 Hz, 1 H,
ArH), 8.05–7.99 (m, 4 H, ArH), 7.85 (t, J = 8.0 Hz, 1 H, ArH),
7.46 (t, J = 8.4 Hz, 1 H, ArH), 7.41 (d, J= 8.0 Hz, 1 H, ArH),
2.32 (s, 3 H, CH3);
13C NMR (DMSO-d6, 100 MHz) d 64.93
(C = O), 163.30 (C = O), 147.82, 141.74, 141.11, 137.40, 137.38,
135.77, 134.36, 134.17, 133.71, 131.56, 130.71, 130.24, 130.04,
127.01, 126.78, 126.17, 125.87, 124.49, 123.46, 123.42, 122.55,
122.36, 18.03; IR (KBr) 3467 (br, NH), 1657 (m, C = O), 1580 (s),
1531 (m), 1417 (m), 1227 (m), 1190 (m), 1040 (m), 835 (w) cm21;
MS (ESI) m/z (M+Na)+ 652, (M+H)+ 630; HRMS (ESI) calcd for
(C25H17N3Na2O10S2+H)+: 630.0229, found 630.0223.
4-[3-(3-Aminobenzamido)-4-
methylbenzamido]naphthalene-1,5-disulphonate Acid
Disodium Salt (7)
Nitro compound 6 (0.103 g, 0.164 mmol, 1.0 equiv) was
dissolved in water (2.0 ml), to which 10% Pd/C (5.0 mg, 5.0%
weight of 6) was added. After the reaction mixture was stirred at
room temperature for 12 hours under H2 atmosphere (4.0 bar),
the Pd/C was filtered off by use of celite pad. Water was removed
under vacuum at 45 uC to give a crude solid, which was then
dissolved in boiling methanol followed by hot filtration. The
residue was dried over P2O5 under vacuum to give 7 (89.1 mg,
0.148 mmol) in 90% yield, as a brown powder: 1H NMR (DMSO-
d6, 400 MHz) d 12.60 (s, 1 H, NH), 9.85 (s, 1 H, NH), 9.09 (d,
J = 8.4 Hz, 1 H, ArH), 8.29 (d, J= 7.2 Hz, 1 H, ArH), 8.04–7.99
(m, 3 H, ArH), 7.96 (s, 1 H, ArH), 7.45 (t, J = 8.0 Hz, 1 H, ArH),
7.36 (d, J= 8.0 Hz, 1 H, ArH), 7.17 (s, 1 H, ArH), 7.14–7.13 (m, 2
H, ArH), 6.76–6.73 (m, 1 H, ArH), 5.30 (br, 2 H, NH2), 2.31 (s, 3
H, CH3);
13C NMR (DMSO-d6, 100 MHz) d 166.18 (C = O),
165.13 (C = O), 148.81, 141.76, 141.03, 137.19, 136.52, 135.38,
134.48, 133.56, 131.58, 130.72, 129.86, 128.78, 127.04, 126.65,
125.30, 125.27, 124.55, 123.48, 122.38, 116.81, 114.78, 113.18,
18.03; IR (KBr) 3356 (br, NH), 3001 (w), 1575 (s), 1423 (m), 1335
(w), 1316 (w), 1223 (m), 1204 (m), 1190 (m), 1042 (m), 836 (w)
cm21; MS (ESI) m/z (M+Na)+ 622, (M+H)+ 600; HRMS (ESI)
calcd for (C25H19N3Na2O8S2+H)+: 600.0487, found 600.0487.
4-49-(Carbonylbis[imino-3,1-phenylenecarbonylimino(4-
methyl-3,1-phenylene) carbonylimino])bis-1,5-
naphthalenedisulphonate Acid Tetrasodium Salt (8)
Aniline derivative 7 (49.4 mg, 82.4 mmol, 2.0 equiv) was
dissolved in water (2.0 ml) and the pH was adjusted to 3.0 by
addition of aqueous Na2CO3 solution (2.0 M). To this solution
triphosgene (33.0 mg, 0.111 mmol, 1.3 equiv) in toluene (0.50 ml)
was slowly added. Its pH value was maintained again at 3.0 by
addition of aqueous Na2CO3 solution (2.0 M). After the reaction
mixture was stirred at room temperature for 12 hours, the toluene
layer was discarded. Water was removed under vacuum at 45 uC
to give a crude solid, which was then dissolved in boiling methanol
followed by hot filtration. The residue was dried over P2O5 under
vacuum to give 8 (42.4 mg, 34.0 mmol) in 83% yield as a white
powder: 1H NMR (DMSO-d6, 400 MHz) d 12.60 (s, 2 H, NH),
11.08 (s, 2 H, NH), 10.07 (s, 2 H, NH), 9.09 (d, J = 8.4 Hz, 2 H,
ArH), 8.29 (d, J = 7.2 Hz, 2 H, ArH), 8.10 (s, 2 H, ArH), 8.057.98
(m, 8 H, ArH), 7.82 (d, 2 H, J= 8.8 Hz, ArH), 7.57 (d, J = 8.0 Hz,
2 H, ArH), 7.45 (t, J= 8.0 Hz, 2 H, ArH), 7.41–7.37 (m, 4 H,
ArH), 2.32 (s, 6 H, 26CH3);
13C NMR (DMSO-d6, 100 MHz) d
165.81 (C = O), 165.06 (C = O), 153.53 (C = O), 141.76, 141.10,
137.18, 136.43, 135.17, 134.42, 133.60, 131.57, 130.72, 129.89,
128.48, 127.01, 126.60, 125.32, 124.51, 123.47, 123.41, 122.36,
121.10, 120.19, 117.60, 114.19, 18.06; IR (KBr) 3355 (br, NH),
2919 (s), 2848 (m), 1652 (s, C = O), 1634 (s, C = O), 1574 (m), 1422
(m), 1318 (m), 1224 (w), 1191 (w), 1086 (w), 1039 (w), 828 (w)
cm21; MS (ESI) m/z (M+2 Na)2+ 635; HRMS (ESI) calcd for
(C51H36N6Na4O17S4+2 Na)2+: 635.0197, found 635.0116.
Water Solubility
A stock solution was prepared by dissolving a precisely weighed
amount of Suramin derivatives in deionized water (1.0 ml). The
UV absorption maximum of each compound was measured by
dilution of the solution with deionized water as necessary. A
saturated solution of each compound was then prepared by use of
deionized water (1.0 ml) in the presence of an excess of Suramin
derivatives for 1.0 hour. The obtained saturated solution was
filtered to remove solid compound through a Millipore filter
(0.45 mm) and was scanned by UV spectroscopy at the wavelength
of the absorption maximum previously determined.
Partition Coefficient
The n-octanol/water partition coefficient of Suramin derivatives
was determined by the shake-flask method. n-Octanol and pH 7.4
phosphate buffer were mutually saturated for 4.0 hours, and the
phases were separated. A stock solution of each Suramin derivative
was prepared using pH 7.4 phosphate buffer solution. Suramin
derivatives were partitioned between n-octanol and pH 7.4
phosphate buffer. Then the phase mixtures were shaken for
1 hour at constant 25 uC. After separation, the absorbance of the
phosphate buffer solutions (pH 7.4) was measured by UV
spectrophotometry. Three replicates were performed for each
compound. The P value corresponded to the quotient between n-
octanol and buffer concentrations of the drug. The log P values
were an average of three independent experiments.
Expression and purification of the hNV and mNV-RdRps
The NV-RdRps were expressed and purified as previously
described [23], and stocked in 25 mM Tris/HCl pH 7.4, 1 mM
DTT, 100 mM NaCl, 1 mM EDTA. Data and/or materials of
NV-RdRps are available for sharing or collaboration following
signing of a material transfer agreement with Riboxx GmbH
(Germany).
In-vitro RdRp inhibition assays
RdRp assays were performed as previously described [23]. In
brief poly(C) (MP Biomedicals) was used as template annealed with
oligoG12 as primer (62.5 nM final concentration) and GTP
(100 mM final concentration) as substrate, in a 200 ml reaction
mixture containing 20 mM Tris/HCl pH 7.5, 25 mM NaCl,
5 mM MgCl2, 0.3 mM MnCl2, 1 mM DTT, PicoGreen Quan-
titation Reagent (Molecular Probes) diluted 1/200 20 U ml21
RiboLock Ribonuclease Inhibitor (Fermentas). Reactions were
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started by the addition of GTP following the fluorescence of
samples in a fluorescence reader (Varian, Cary Eclipse Fluores-
cence Spectrophotometer).
Thermofluorometric characterization of the hNV-RdRp
inhibitors interaction
Thermofluorimetric (Thermal shift) assays for the evaluation of
the hNV-RdRp melting temperature (Tm) in the absence/presence
of the inhibitors, were conducted in a MiniOpticon Real Time
PCR Detection System (Bio-Rad), using the fluorescent dye Sypro
Orange. Solutions of 4 ml of the NV-RdRp domain (final hNV-
RdRp concentration 7 mM, final mNV-RdRp concentration
1.6 mM) were diluted in 9.5 ml of its buffer, and mixed with
3.5 ml of Sypro orange (Sigma) diluted 606, and 1 ml of 6 or 8
(4 mM final concentration). In control samples the inhibitors were
replaced by water. The sample plates were heated from 20 to 90uC
with a heating rate of 0.2 uC/min. Fluorescence intensities were
measured within excitation/emission ranges of 470–505 nm and
540–700 nm, respectively.
Crystallization of the NV-RdRps in presence of 6
Sitting drop crystallization experiments on hNV-RdRp (11 mg/
ml) were prepared using an Oryx-8 crystallization robot (Douglas
Instruments, East Garston, UK), from a 50% mixture of the
protein with the reservoir solution (final drop volume 0.3 ml).
Crystals were obtained after 4 weeks at 20uC, in 1.2 M Na citrate,
100 mM Na cacodylate pH 6.2, and NaCl 125 mM. Before X-ray
data collection, crystals were soaked in a cryoprotectant solution
(1.4 M Na citrate, 100 mM Na cacodylate pH 6.2, and 25%
glycerol) with 10 mM 6, in the presence of 62.5 nM dsRNA and
100 mM GTP for 36 hours, then flash-cooled in liquid nitrogen.
The hNV-RdRp/6 crystals diffracted to a maximum resolution of
2.02 A˚ at the ESRF Synchrotron (Grenoble, France) beam line
ID29. X-ray diffraction data were indexed using MOSFLM [38],
and intensities were merged using SCALA [39]. Microbatch
crystallization experiments on mNV-RdRp were prepared using
an Oryx-8 crystallization robot (Douglas Instruments, East
Garston, UK), from a 2:1:1 mixture (drop volume 0.4 ml) of
protein (10 mg/ml), precipitant, and 100 mM MgCl2 (25 mM in
the drop), covered by Al’s oil (a mixture of 50% Paraffin oil and
50% Silicon oil). Prismatic crystals of approximately
150680630 mm3 were obtained after 1 week at 20uC, in 1.6 M
(NH4)2SO4, 12% glycerol, 100 mM TRIS-HCl pH 8.4. Before X-
ray data collection, crystals were soaked in a cryoprotectant
solution (1.8 M (NH4)2SO4, 100 mM TRIS-HCl pH 8.4, and
25% glycerol) with 20 mM of 6, in the presence of 62.5 nM of
dsRNA and 100 mM of GTP for 36 hours, than flash-cooled in
liquid nitrogen. dsRNA and GTP were added to the soaking
solution as additives to increase chances to obtain ligand-protein
complexes The mNV-RdRp/6 crystals diffracted to a maximum
resolution of 2.3 A˚ at the ESRF Synchrotron (Grenoble, France)
beam line ID29. X-ray diffraction data were indexed using
MOSFLM, and intensities were merged using SCALA [39].
Structure determination and refinement
The three-dimensional structures of hNV-RdRp and mNV-
RdRp in the complexes with 6 were solved by the Molecular
Replacement method using the program MOLREP [40] and as
search models the 3D structures of the respective ligand-free
RdRps (PDB-id 2B43 and id 3UQS, respectively). The crystal
asymmetric unit molecule(s) were individually subjected to rigid-
body refinement, and subsequently to restrained refinement using
REFMAC5 [41]. A random set comprising 5% of the data was
omitted from refinement for R-free calculation. Manual rebuilding
with COOT [42] and additional refinement with BUSTER [43]
and REFMAC5 were subsequently performed, as needed. Data
collection, refinement statistics as well as stereochemical quality of
the models are summarized in Table 3. Atomic coordinates and
structure Factor files for hNV-RdRp/6 and mNV-RdRp/6
complexes have been deposited with the Protein Data Banks as
entries 4NRT and 4NRU, respectively.
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